U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287670) titled 'EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)' on Nov. 18.
Brief Summary: A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Diffuse Cutaneous Systemic Sclerosis
Intervention:
BIOLOGICAL: MTX-474
Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being ...